FY2025 Earnings Forecast for Geron Issued By B. Riley

Geron Co. (NASDAQ:GERN - Free Report) - Equities researchers at B. Riley dropped their FY2025 earnings per share (EPS) estimates for shares of Geron in a research report issued to clients and investors on Tuesday, February 18th. B. Riley analyst K. Patel now forecasts that the biopharmaceutical company will post earnings of ($0.08) per share for the year, down from their previous forecast of ($0.03). B. Riley has a "Buy" rating and a $3.50 price objective on the stock. The consensus estimate for Geron's current full-year earnings is ($0.25) per share. B. Riley also issued estimates for Geron's FY2026 earnings at $0.12 EPS.

Several other research analysts also recently commented on the stock. Barclays upgraded shares of Geron to a "strong-buy" rating in a research report on Friday, November 29th. HC Wainwright reiterated a "buy" rating and issued a $9.00 price target on shares of Geron in a research note on Tuesday, December 10th. Finally, Needham & Company LLC upped their price objective on Geron from $6.00 to $7.00 and gave the stock a "buy" rating in a research report on Monday, January 13th. One analyst has rated the stock with a sell rating, one has given a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $6.91.

Geron Price Performance

Geron stock traded down $0.06 during trading hours on Thursday, reaching $2.58. 8,953,629 shares of the stock were exchanged, compared to its average volume of 11,789,383. The stock has a 50 day moving average of $3.11 and a two-hundred day moving average of $3.87. Geron has a twelve month low of $1.64 and a twelve month high of $5.34. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04. The company has a market cap of $1.56 billion, a P/E ratio of -8.05 and a beta of 0.53.

Institutional Trading of Geron

Hedge funds have recently made changes to their positions in the company. SBI Securities Co. Ltd. bought a new stake in shares of Geron in the fourth quarter worth $28,000. Integrated Wealth Concepts LLC acquired a new position in Geron during the 4th quarter worth about $36,000. GF Fund Management CO. LTD. bought a new stake in shares of Geron in the 4th quarter valued at about $45,000. Fifth Lane Capital LP acquired a new stake in shares of Geron in the fourth quarter valued at about $53,000. Finally, Readystate Asset Management LP bought a new position in shares of Geron during the third quarter worth about $58,000. 73.71% of the stock is owned by institutional investors and hedge funds.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.